ATE414534T1 - Immunotherapeutische methoden und systeme - Google Patents

Immunotherapeutische methoden und systeme

Info

Publication number
ATE414534T1
ATE414534T1 AT02783303T AT02783303T ATE414534T1 AT E414534 T1 ATE414534 T1 AT E414534T1 AT 02783303 T AT02783303 T AT 02783303T AT 02783303 T AT02783303 T AT 02783303T AT E414534 T1 ATE414534 T1 AT E414534T1
Authority
AT
Austria
Prior art keywords
methods
polypeptide antigen
peptides
antigen
systems
Prior art date
Application number
AT02783303T
Other languages
English (en)
Inventor
Mark Larche
Philip William Ledger
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23324613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE414534(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Circassia Ltd filed Critical Circassia Ltd
Application granted granted Critical
Publication of ATE414534T1 publication Critical patent/ATE414534T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
AT02783303T 2001-12-05 2002-12-05 Immunotherapeutische methoden und systeme ATE414534T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33838501P 2001-12-05 2001-12-05

Publications (1)

Publication Number Publication Date
ATE414534T1 true ATE414534T1 (de) 2008-12-15

Family

ID=23324613

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02783303T ATE414534T1 (de) 2001-12-05 2002-12-05 Immunotherapeutische methoden und systeme

Country Status (9)

Country Link
US (2) US20060024334A1 (de)
EP (1) EP1453539B1 (de)
JP (2) JP4874522B2 (de)
AT (1) ATE414534T1 (de)
AU (1) AU2002347369A1 (de)
CA (1) CA2469078A1 (de)
DE (1) DE60229979D1 (de)
ES (1) ES2316632T3 (de)
WO (1) WO2003047618A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2469078A1 (en) * 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
US7279295B2 (en) * 2002-03-27 2007-10-09 Phadia Ab Allergen
EP1504089A2 (de) * 2002-05-16 2005-02-09 Alk Abell A/S Allergenmutanten
GB0307989D0 (en) * 2003-04-07 2003-05-14 Mcewen Lab Ltd Therapeutic composition
KR20060096030A (ko) * 2003-09-17 2006-09-05 베이비 부스트 인코퍼레이티드 알레르기 방지 방법 및 기구
DE10351471A1 (de) * 2003-11-04 2005-06-09 Ursula Prof. Dr. Wiedermann-Schmidt Polyvalente Allergievakzine
EP1773402A2 (de) * 2004-06-17 2007-04-18 Mannkind Corporation Wirksamere immuntherapie mittels ergänzung diagnostischer verfahren mit therapeutischen verfahren
CN100374152C (zh) 2005-12-23 2008-03-12 中国农业大学 一种过敏性反应抑制剂
JP2007189919A (ja) * 2006-01-17 2007-08-02 Osaka Prefecture Univ イヌアレルギーに対する予防又は治療作用を有するポリペプチド
JP2007189920A (ja) * 2006-01-17 2007-08-02 Osaka Prefecture Univ イヌアレルギーに対する予防又は治療作用を有するポリペプチド
EP2423219B1 (de) 2007-01-30 2015-04-29 Epivax, Inc. Regulatorische T-Zellen-Epitope sowie Zusammensetzungen damit und Anwendungen davon
MX2009007929A (es) * 2007-01-30 2009-08-07 Alk Abello As Uso de un primer alergeno del grupo 2 de acaro de polvo de casa para tratar alergia a un segundo alergeno del grupo 2 de acaro de polvo de casa.
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
AU2013202871B2 (en) * 2007-06-01 2015-10-22 Circassia Limited Vaccine peptide combinations against cat allergy
EA023303B1 (ru) * 2007-08-15 2016-05-31 Сиркейшиа Лимитед Пептидная композиция для формирования толерантности к клещам домашней пыли и ее применение
EP2331124A1 (de) * 2008-08-15 2011-06-15 Circassia Limited T-zell-antigen-peptid aus einem allergen zur stimulierung der il-10-produktion
ES2378870T5 (es) 2008-08-15 2016-02-03 Circassia Limited Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
MX346450B (es) 2008-11-30 2017-03-17 Immusant Inc * Composiciones y métodos para el tratamiento de la enfermedad celíaca.
ES2532759T3 (es) 2009-02-05 2015-03-31 Circassia Limited Péptidos de plantas herbáceas para vacunas
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
WO2011106645A1 (en) * 2010-02-26 2011-09-01 Benaroya Research Institute Direct analysis of antigen-specific immune response
WO2011112788A1 (en) * 2010-03-12 2011-09-15 Antigen Laboratories, Inc. Methods of treating allergies with substantially phenol-free carriers
US9271899B2 (en) * 2010-04-30 2016-03-01 Allovate, Llc Methods, articles and kits for allergic desensitization, via the oral mucosa
EP2681555B1 (de) 2011-02-25 2020-04-08 Benaroya Research Institute Allergienachweis
EP2524701A3 (de) * 2011-05-20 2012-12-19 Nitto Denko Corporation Pharmazeutische Zusammensetzung und Herstellungsverfahren dafür
WO2013166453A2 (en) * 2012-05-03 2013-11-07 La Jolla Institute For Allergy And Immunology T cell epitopes from cockroach and methods of making and using same
GB201208293D0 (en) 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
JP6608282B2 (ja) 2012-10-30 2019-11-20 アラヴァックス ピーティーワイ リミテッド 新規免疫療法用分子およびその使用
JP2014028820A (ja) * 2013-08-30 2014-02-13 China Agricultural Univ アレルギー抑制剤の組成物及びキットならびにその使用方法
CA2923822A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
EA035045B1 (ru) 2013-09-19 2020-04-21 АЛЛОВЕЙТ, ЭлЭлСи Составы зубной пасты для доставки аллергенов в слизистую оболочку полости рта
RU2689552C2 (ru) 2013-09-25 2019-05-28 Аравакс Пти Лтд Новая иммунотерапевтическая композиция и ее применения
ES2665180T3 (es) * 2014-03-18 2018-04-24 Apeptico Forschung Und Entwicklung Gmbh Medicamento de péptido en forma de polvo seco
US10872313B2 (en) 2015-06-02 2020-12-22 ROCA Medical Ltd. Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
CA2962933A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
US20160362205A1 (en) * 2015-06-02 2016-12-15 ROCA Medical Ltd. Use of autoinjector for distributing antigens to the public
US10548974B2 (en) 2015-06-02 2020-02-04 ROCA Medical Ltd. Therapeutic treatment kit for allergies based on DNA profiles
US10369215B2 (en) 2015-06-02 2019-08-06 ROCA Medical Ltd. Predilution sets for distributing antigens
US20170021010A1 (en) * 2015-07-21 2017-01-26 David Phillip ERSTEIN Allergy preventing dosage controlled food packets
JP7041923B2 (ja) * 2016-03-03 2022-03-25 学校法人藤田学園 大豆アレルギーの抗原
CN108265057B (zh) * 2016-12-31 2019-10-18 江苏众红生物工程创药研究院有限公司 一种重组户尘螨2类变应原蛋白及其制备方法和应用
CN108265059B (zh) * 2016-12-31 2021-01-05 江苏众红生物工程创药研究院有限公司 一种重组粉尘螨2类变应原蛋白及其制备方法与应用
JP7555788B2 (ja) * 2020-10-30 2024-09-25 アサヒグループホールディングス株式会社 タンパク質の起源種判別方法
CN113336862B (zh) * 2021-07-05 2022-03-01 广东省科学院动物研究所 一种抗多发性硬化的重组蛋白及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358710A (en) * 1989-12-01 1994-10-25 Alec Sehon Method for the suppression of an immune response
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
CA2186873A1 (en) * 1994-04-01 1995-10-12 Charles J. Hackett Haptenated peptides and uses thereof
CA2317724A1 (en) * 1998-01-09 1999-07-15 Circassia Limited Methods and compositions for desensitisation
CA2469078A1 (en) * 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems

Also Published As

Publication number Publication date
JP2009292838A (ja) 2009-12-17
JP4874522B2 (ja) 2012-02-15
CA2469078A1 (en) 2003-06-12
EP1453539B1 (de) 2008-11-19
ES2316632T3 (es) 2009-04-16
US20060024334A1 (en) 2006-02-02
WO2003047618A2 (en) 2003-06-12
AU2002347369A8 (en) 2003-06-17
US20110142867A1 (en) 2011-06-16
DE60229979D1 (de) 2009-01-02
EP1453539A2 (de) 2004-09-08
AU2002347369A1 (en) 2003-06-17
WO2003047618A3 (en) 2004-01-08
JP2005518367A (ja) 2005-06-23

Similar Documents

Publication Publication Date Title
AU2002347369A8 (en) Immunotherapeutic methods and systems
HUP9901109A2 (hu) Immunogén peptidek vakcinálásra és allergia kezelésére
WO2002072636A8 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2005013896A3 (en) Programmed immune responses using a vaccination node
NO20014131L (no) Epitoper eller mimotoper avledet fra C-epsilon-3- eller C- epsilon-4-domener fra IgE, antagonister derav og deresterapeutiske anvendelser
WO2003028757A1 (en) Novel method of inducing antigen-specific t cells
BRPI0412245A (pt) anticorpos de rg1 e usos destes
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
EP2502998A3 (de) Rekombinanter Toxin A-/Toxin B-Impfstoff gegen Clostridium difficile
ATE544470T1 (de) Immuntherapeutische methoden und zusammensetzungen
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
RU2019113989A (ru) Лекарственное средство
NO20050066L (no) Pegylert T20 polypeptid
WO2007145760A3 (en) Anthrax compositions and methods of use and production
AU2003241127A8 (en) Membrane-anchored beta2 microglobulin covalently linked to mhc class i peptide epitopes
ATE466879T1 (de) 5t4-antigen-peptidepitope der mhc klasse ii
DE69720065D1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
ATE360642T1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
WO2003059953A3 (en) Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
MX2023014318A (es) Metodos de tratamiento mejorados utilizando peptidos inmunogenicos.
DE60109922D1 (de) Therapeutische verbindungen gegen eierstockkrebs
ATE467421T1 (de) Cytokine und cytokinrezeptoren mit reduzierter immunogenität
PL379549A1 (pl) Autologiczne, indukujące tolerancję na antygeny własne komórki pochodzenia monocytarnego oraz ich zastosowanie w preparatach farmaceutycznych
WO2002034288A3 (en) Vaccine for treating allergy
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties